Pierre Marquet has been a Doctor of Medicine since 1986 and obtained a master in statistics and epidemiology followed by a PhD in physiology in 1992. After several years as an assistant professor at Limoges University Hospital, he became an associate professor of pharmacology in 1998 and since 2001, has been a full professor at the Faculty of Medicine of Limoges, France. He was presented with the Young Scientist Award of the French Society of Analytical Toxicology in 1995, the IATDMCT Young Investigator Award in 2001 and C.E. Pippenger Award in 2009. At the IATDMCT, he chaired the Standard of Laboratory Practice Committee from 2001-2007, was elected Secretary in 2007 and then President-elect in 2009.
Pierre Marquet is currently:
- Director of the INSERM U850 research unit called “Pharmacology of immunosuppressive drugs in transplantation”
(INSERM is the French Institute of Medical and Health Research)
- Head of the “Pharmacology, Toxicology and Pharmacovigilance” Department at the University Hospital of Limoges
- Vice-President of the board of Directors of University Hospital of Limoges, in charge of research
- Member of the council of the French Society of Pharmacology and Therapeutics (SFPT)
- Coordinator of the “drugs and pharmacology” working group of the French-speaking Society of Transplantation (SFT)
- Member of several scientific committees
Pierre Marquet conducts translational research on treatment personalization, mainly concerning immunosuppressants (IS) in organ transplantation, which covers: new analytical methodologies for IS; metabolic, pharmacogenetic and pharmacodynamic studies of the IS; investigation of early biomarkers; epidemiological studies and clinical trials in transplant patients; and application to routine treatment personalization in transplant recipients. He has published over 160 papers in peer-reviewed, international journals. He is the coordinator of the European research program “Biomarkers of Renal Graft Injuries” (BIOMARGIN, FP7 Health).